ViewPoint Therapeutics Overview
- Founded
-
2014

- Status
-
Private
- Employees
-
11

- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$61.4K
- Investors
-
14
ViewPoint Therapeutics General Information
Description
Developer of crystallin stabilizers designed to prevent and treat cataracts and presbyopia. The company's crystallin stabilizers include a small molecule that is active in preclinical models of age-related cataracts via a target-based screening and optimization effort, enabling physicians to have drugs that prevent or reverse protein misfolding, which is implicated in numerous common disorders of aging including cataracts, presbyopia, and neurodegenerative diseases.
Contact Information
Website
www.viewpointtherapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- 953 Indiana Street
- San Francisco, CA 94107
- United States
+1 (734) 000-0000
ViewPoint Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
6. Later Stage VC | 08-Nov-2019 | $61.4K | 0000 | Completed | Generating Revenue | |
5. Early Stage VC (Series B) | 05-Mar-2018 | 0000 | 0000 | 0000 | Completed | Generating Revenue |
4. Early Stage VC (Series A) | 02-May-2016 | 00.000 | 00.000 | 000.00 | Completed | Generating Revenue |
3. Grant | 01-Apr-2016 | 00000 | Completed | Generating Revenue | ||
2. Accelerator/Incubator | Completed | Generating Revenue | ||||
1. Accelerator/Incubator | 06-Oct-2014 | Completed | Generating Revenue |
ViewPoint Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series B | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Series A | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
ViewPoint Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of crystallin stabilizers designed to prevent and treat cataracts and presbyopia. The company's crystallin sta
Drug Discovery
San Francisco, CA
11
As of 2020
0000
0000000000 0
0000
ViewPoint Therapeutics Competitors (26)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Escape Bio | Venture Capital-Backed | San Francisco, CA | 00 | 00000 | 00000000000 | 00000 |
00000000000 | Venture Capital-Backed | Boston, MA | 00 | 00000 | 00000000000 | 00000 |
00000000 000000000 | Venture Capital-Backed | Cambridge, MA | 00 | 00000 | 00000000000 | 00000 |
0000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 000000 - 000 | 00000 |
0000000 | Venture Capital-Backed | Framingham, MA | 00 | 000.00 | 00000000000 | 000.00 |
ViewPoint Therapeutics Patents
ViewPoint Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-3347368-A4 | Compounds and formulations for treating ophthalmic diseases | Withdrawn | 08-Sep-2015 | 0000000000 | 0 |
JP-2018526423-A | Compounds and formulations for treating ophthalmic diseases | Pending | 08-Sep-2015 | 0000000000 | |
EP-3347368-A1 | Compounds and formulations for treating ophthalmic diseases | Withdrawn | 08-Sep-2015 | 0000000000 | |
US-20180250313-A1 | Compounds and formulations for treating ophthalmic diseases | Abandoned | 08-Sep-2015 | 0000000000 | |
AU-2016321254-A1 | Compounds and formulations for treating ophthalmic diseases | Abandoned | 08-Sep-2015 | A61K31/575 |
ViewPoint Therapeutics Executive Team (8)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Noelynn Oliver | Senior Director, Biology |
ViewPoint Therapeutics Board Members (7)
Name | Representing | Role | Since |
---|---|---|---|
Edward Hurwitz | Self | Chairman | 000 0000 |
Emmett Cunningham Ph.D | ViewPoint Therapeutics | Board Member | 000 0000 |
Heath Lukatch Ph.D | TPG | Board Member | 000 0000 |
Peter Moldt Ph.D | Novo Holdings | Board Member | 000 0000 |
ViewPoint Therapeutics Signals
ViewPoint Therapeutics Investors (14)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Novo Holdings | Venture Capital | Minority | 000 0000 | 000000 0 | |
The Rise Fund | Impact Investing | Minority | 000 0000 | 000000 0 | |
TPG | PE/Buyout | Minority | 000 0000 | 000000 0 | |
Asset Management Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
BVF Partners | Hedge Fund | Minority | 000 0000 | 000000 0 |